Innovating Women’s Reproductive Health and Pregnancy Therapeutics ObsEva is a biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics from conception to birth. Between the ages of 20 and 50, millions of women worldwide suffer from reproductive health conditions that affect their quality of life and their ability to conceive or may lead to complications during pregnancy. ObsEva aims to improve upon the current treatment landscape with the development of novel, oral medicines with potentially best-in-class safety and efficacy profiles. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with multiple development programs focused on treating endometriosis, uterine fibroids, and preterm labor. ObsEva is supported by top-tier investors and a globally recognized board and is well-positioned to establish a leadership position in women’s reproductive therapeutics.
Type
Private
HQ
Plan-les-Ouates, CH
Founded
2012
Employees
27 (est)

Key People at ObsEva

Ernest Loumaye

Ernest Loumaye

Co-Founder & CEO
André Chollet

André Chollet

Co-Founder & CSO

ObsEva Locations

Plan-les-Ouates, CH

ObsEva Metrics

ObsEva Summary

Founding Date

2012

Total Funding

$92.9 M

Latest funding size

$60 M

Time since last funding

about 1 year

Investors

ObsEva Company Life

You may also be interested in